

Christos Chouaid

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4449967/publications.pdf>

Version: 2024-02-01

290
papers

14,002
citations

44042

48
h-index

24961

109
g-index

346
all docs

346
docs citations

346
times ranked

14781
citing authors

#	ARTICLE	IF	CITATIONS
1	Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. <i>Lancet</i> , The, 2009, 373, 1525-1531.	6.3	1,321
2	Durvalumab plus platinum+etoposide versus platinum+etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2019, 394, 1929-1939.	6.3	1,274
3	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2015, 16, 257-265.	5.1	1,269
4	A Randomized Study of Endobronchial Valves for Advanced Emphysema. <i>New England Journal of Medicine</i> , 2010, 363, 1233-1244.	13.9	704
5	Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives. <i>Journal of Clinical Oncology</i> , 2013, 31, 1997-2003.	0.8	572
6	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 521-536.	5.1	486
7	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 763-774.	5.1	431
8	Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1476-1483.	0.8	333
9	Shortened Telomeres in Circulating Leukocytes of Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 566-571.	2.5	273
10	Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3516-3524.	0.8	214
11	Invasive aspergillosis in patients with acquired immunodeficiency syndrome: Report of 33 cases. <i>American Journal of Medicine</i> , 1993, 95, 177-187.	0.6	203
12	Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. <i>Clinical Cancer Research</i> , 2015, 21, 1896-1903.	3.2	199
13	Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018. <i>Journal of Thoracic Oncology</i> , 2020, 15, 628-636.	0.5	185
14	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 212-223.	5.1	158
15	Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01). <i>Lung Cancer</i> , 2014, 86, 170-173.	0.9	156
16	Role for Interleukin-6 in COPD-Related Pulmonary Hypertension. <i>Chest</i> , 2009, 136, 678-687.	0.4	152
17	Maintenance bevacizumab+pemetrexed after first-line cisplatin+pemetrexed+bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. <i>Annals of Oncology</i> , 2014, 25, 1044-1052.	0.6	152
18	Multicentre phase II study of cisplatin+etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. <i>Annals of Oncology</i> , 2013, 24, 1548-1552.	0.6	135

#	ARTICLE	IF	CITATIONS
19	Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. <i>British Journal of Cancer</i> , 2008, 99, 2006-2012.	2.9	129
20	Pulmonary Artery Smooth Muscle Cell Senescence Is a Pathogenic Mechanism for Pulmonary Hypertension in Chronic Lung Disease. <i>Circulation Research</i> , 2011, 109, 543-553.	2.0	126
21	Lung cancer and interstitial lung disease: a literature review. <i>Journal of Thoracic Disease</i> , 2018, 10, 3829-3844.	0.6	126
22	Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment. <i>Clinical Microbiology and Infection</i> , 2018, 24, 216-218.	2.8	125
23	Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 328-337.	5.1	124
24	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016, 27, 417-423.	0.6	122
25	Pulmonary Cryptococcosis: Localized and Disseminated Infections in 27 Patients with AIDS. <i>Clinical Infectious Diseases</i> , 1995, 21, 628-633.	2.9	118
26	Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC O601). <i>Journal of Thoracic Oncology</i> , 2011, 6, 576-582.	0.5	107
27	Health-Related Quality of Life and Utility in Patients with Advanced Non-Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting. <i>Journal of Thoracic Oncology</i> , 2013, 8, 997-1003.	0.5	100
28	Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. <i>Lung Cancer</i> , 2018, 116, 62-66.	0.9	94
29	Imbalance between Platelet Vascular Endothelial Growth Factor and Platelet-derived Growth Factor in Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 1493-1499.	2.5	90
30	The association between asthma control, health care costs, and quality of life in France and Spain. <i>BMC Pulmonary Medicine</i> , 2013, 13, 15.	0.8	90
31	Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. <i>BMC Medicine</i> , 2011, 9, 7.	2.3	86
32	Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1224-1233.	5.1	80
33	Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis. <i>Lung Cancer</i> , 2020, 140, 99-106.	0.9	79
34	Target lobe volume reduction and COPD outcome measures after endobronchial valve therapy. <i>European Respiratory Journal</i> , 2014, 43, 387-396.	3.1	73
35	Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. <i>Targeted Oncology</i> , 2017, 12, 563-569.	1.7	71
36	Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project Part 2). <i>Journal of Thoracic Oncology</i> , 2012, 7, 1490-1502.	0.5	69

#	ARTICLE	IF	CITATIONS
37	Whole-Brain Radiation Therapy Plus Concomitant Temozolomide for the Treatment of Brain Metastases From Non-Small-Cell Lung Cancer: A Randomized, Open-Label Phase II Study. <i>Clinical Lung Cancer</i> , 2010, 11, 176-181.	1.1	67
38	BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers. <i>European Respiratory Journal</i> , 2015, 45, 1403-1414.	3.1	66
39	Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 576-584.	0.5	62
40	Impact of a multidisciplinary approach to the control of antibiotic prescription in a general hospital. <i>Journal of Hospital Infection</i> , 2003, 53, 177-182.	1.4	61
41	Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2009, 65, 345-350.	0.9	60
42	Interleukin-6 Gene Polymorphism Confers Susceptibility to Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 475a-476.	3.5	59
43	Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study.. <i>Journal of Clinical Oncology</i> , 2010, 28, 7507-7507.	0.8	59
44	Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model.. <i>Journal of Clinical Oncology</i> , 1998, 16, 2700-2707.	0.8	55
45	A Web-Based Delphi Study on the Indications of Chest Radiographs for Patients in ICUs. <i>Chest</i> , 2008, 133, 1107-1112.	0.4	53
46	Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status for the Administration of EGFR-TKIs in Tj ETQq0 0 0 r05 /Overlook 10 Tf 5	0.5	52
47	1006-1015. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. <i>Lung Cancer</i> , 2019, 127, 44-52.	0.9	52
48	Economics of the clinical management of lung cancer in France: an analysis using a Markov model. <i>British Journal of Cancer</i> , 2004, 90, 397-402.	2.9	51
49	Risk Factors for Isolation of Streptococcus pneumoniae with Decreased Susceptibility to Penicillin G from Patients Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 1996, 22, 437-440.	2.9	50
50	Delays for diagnosis and treatment of lung cancers: a systematic review. <i>Clinical Respiratory Journal</i> , 2016, 10, 267-271.	0.6	50
51	Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). <i>Annals of Oncology</i> , 2013, 24, 2875-2880.	0.6	48
52	CPAP titration by an auto-CPAP device based on snoring detection: a clinical trial and economic considerations. <i>European Respiratory Journal</i> , 1998, 12, 759-763.	3.1	46
53	Frequency of comorbidities in chronic obstructive pulmonary disease, and impact on all-cause mortality: A population-based cohort study. <i>Respiratory Medicine</i> , 2016, 117, 33-39.	1.3	45
54	Chronic bronchitis in the general population: Influence of age, gender and socio-economic conditions. <i>Respiratory Medicine</i> , 2012, 106, 467-471.	1.3	44

#	ARTICLE	IF	CITATIONS
55	Use of the Polymerase Chain Reaction Technique on Induced-Sputum Samples for the Diagnosis of <i>Pneumocystis carinii</i> Pneumonia in HIV-infected Patients: A Clinical and Cost-Analysis Study. <i>American Journal of Clinical Pathology</i> , 1995, 104, 72-75.	0.4	43
56	Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. <i>European Respiratory Journal</i> , 2012, 39, 172-179.	3.1	43
57	First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors. <i>BioDrugs</i> , 2019, 33, 159-171.	2.2	40
58	Safety of combined PD-1 pathway inhibition and radiation therapy for non-small cell lung cancer: A multicentric retrospective study from the GFPC. <i>Cancer Medicine</i> , 2018, 7, 5505-5513.	1.3	39
59	Economics of Treatments for Non-Small Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2009, 27, 113-125.	1.7	38
60	Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors. <i>Targeted Oncology</i> , 2018, 13, 501-507.	1.7	38
61	Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. <i>Lung Cancer</i> , 2020, 147, 137-142.	0.9	37
62	Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14 skipping mutation: A series of 6 cases. <i>Lung Cancer</i> , 2020, 150, 21-25.	0.9	36
63	Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	1.1	36
64	Simulation-Based Estimates of Effectiveness and Cost-Effectiveness of Smoking Cessation in Patients with Chronic Obstructive Pulmonary Disease. <i>PLoS ONE</i> , 2011, 6, e24870.	1.1	35
65	First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study. <i>Cancer Medicine</i> , 2020, 9, 2309-2316.	1.3	35
66	Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing Docetaxel and Pemetrexed: The GFPC 05-06 Study. <i>Journal of Thoracic Oncology</i> , 2011, 6, 161-168.	0.5	34
67	Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1496-1502.	0.5	34
68	Economic burden of resected (stage IB-III A) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS). <i>Lung Cancer</i> , 2018, 124, 298-309.	0.9	34
69	ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date. <i>Current Oncology</i> , 2022, 29, 641-658.	0.9	34
70	Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies. <i>Clinical Biochemistry</i> , 2000, 33, 405-410.	0.8	33
71	An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1529-1537.	0.5	33
72	Anti-PD-(L)1 for KRAS-mutant advanced non-small cell lung cancers: a meta-analysis of randomized controlled trials. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 719-726.	2.0	33

#	ARTICLE	IF	CITATIONS
73	Polycythemia Impairs Vasodilator Response to Acetylcholine in Patients with Chronic Hypoxemic Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 157, 1452-1460.	2.5	32
74	Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis. <i>Current Medical Research and Opinion</i> , 2007, 23, 1509-1515.	0.9	32
75	Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. <i>Lung Cancer</i> , 2019, 127, 96-102.	0.9	31
76	Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab. <i>Cancers</i> , 2020, 12, 2234.	1.7	31
77	Increased erythropoietin synthesis in patients with COLD or left heart failure is related to alterations in renal haemodynamics. <i>European Journal of Clinical Investigation</i> , 2001, 31, 103-109.	1.7	30
78	A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study). <i>British Journal of Cancer</i> , 2011, 105, 1123-1130.	2.9	30
79	Aging-Related Systemic Manifestations in COPD Patients and Cigarette Smokers. <i>PLoS ONE</i> , 2015, 10, e0121539.	1.1	30
80	Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. <i>Lung Cancer</i> , 2011, 74, 529-534.	0.9	29
81	Hospital admissions related to acute exacerbations of chronic obstructive pulmonary disease in France, 1998â€“2007. <i>Respiratory Medicine</i> , 2011, 105, 595-601.	1.3	29
82	Cost-Benefit Analysis of a Simulated Institution-Based Preoperative Smoking Cessation Intervention in Patients Undergoing Total Hip and Knee Arthroplasties in France. <i>Chest</i> , 2009, 135, 477-483.	0.4	28
83	Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units. <i>Intensive Care Medicine</i> , 2015, 41, 164-165.	3.9	28
84	Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. <i>Annals of Oncology</i> , 2014, 25, 2147-2155.	0.6	27
85	No impact of passive smoke on the somatic profile of lung cancers in never-smokers. <i>European Respiratory Journal</i> , 2015, 45, 1415-1425.	3.1	27
86	Adjuvant treatment patterns and outcomes in patients with stage IB-IIIa non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. <i>Lung Cancer</i> , 2018, 124, 310-316.	0.9	27
87	Cost of Lung Cancer. <i>Pharmacoeconomics</i> , 2006, 24, 651-659.	1.7	26
88	A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study). <i>Lung Cancer</i> , 2012, 77, 97-103.	0.9	26
89	Interactions between HIV infection and chronic obstructive pulmonary disease: Clinical and epidemiological aspects. <i>Respiratory Research</i> , 2011, 12, 117.	1.4	25
90	Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study). <i>Oncotarget</i> , 2018, 9, 8253-8262.	0.8	25

#	ARTICLE	IF	CITATIONS
91	Cost Effectiveness of Noninvasive Oxygen Saturation Measurement During Exercise for the Diagnosis of Pneumocystis carinii Pneumonia. <i>The American Review of Respiratory Disease</i> , 1993, 147, 1360-1363.	2.9	24
92	An open multicenter phase II trial of docetaxel + gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage III B pleural/IV non-small-cell lung cancer (NSCLC): The GFPC 02-02a study. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 64, 73-81.	2.0	24
93	Health-Related Quality of Life in Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089). <i>Journal of Thoracic Oncology</i> , 2013, 8, 1409-1416.	0.5	24
94	Targeted therapy for localized non-small-cell lung cancer: a review. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4099-4104.	1.0	24
95	Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC IFCT 02-01. <i>European Journal of Cancer</i> , 2016, 52, 181-187.	1.3	24
96	Oral second- and third-line lomustine + etoposide + cyclophosphamide chemotherapy for small cell lung cancer. <i>Lung Cancer</i> , 2010, 67, 188-193.	0.9	23
97	Medical follow-up of workers exposed to lung carcinogens: French evidence-based and pragmatic recommendations. <i>BMC Public Health</i> , 2017, 17, 191.	1.2	23
98	Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma. <i>Medicine (United States)</i> , 2020, 99, e18726.	0.4	23
99	Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy. <i>Lung Cancer</i> , 2021, 159, 45-55.	0.9	23
100	Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 31.	0.7	21
101	Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 145, 1305-1311.	0.4	21
102	Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 801-807.	0.5	21
103	Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatinib plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatinib. <i>LUX-Lung 5 (115)</i> . <i>Journal of Clinical Oncology</i> , 2014, 32, 8019-8019.	0.8	21
104	Management of nosocomial pneumonia on a medical ward: a comparative study of outcomes and costs of invasive procedures. <i>Clinical Microbiology and Infection</i> , 2009, 15, 165-172.	2.8	20
105	Causes of Pleural Effusion in 75 HIV-infected Patients. <i>Chest</i> , 1993, 104, 655.	0.4	19
106	A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer. <i>Lung Cancer</i> , 2012, 76, 465-471.	0.9	19
107	A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer. <i>BMC Cancer</i> , 2014, 14, 231.	1.1	19
108	Efficacy of next treatment received after nivolumab progression in patients with advanced non-small cell lung cancer. <i>ERJ Open Research</i> , 2018, 4, 00120-2017.	1.1	19

#	ARTICLE	IF	CITATIONS
109	PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093797.	1.4	19
110	Pulmonary cryptosporidiosis in the acquired immunodeficiency syndrome. <i>Infection</i> , 1996, 24, 328-331.	2.3	18
111	Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anemia: A Markov analysis. <i>Lung Cancer</i> , 2006, 51, 369-376.	0.9	18
112	An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study. <i>Lung Cancer</i> , 2007, 57, 72-78.	0.9	18
113	Effects of polycythemia on systemic endothelial function in chronic hypoxic lung disease. <i>Journal of Applied Physiology</i> , 2011, 110, 1196-1203.	1.2	18
114	Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study. <i>Lung Cancer</i> , 2014, 85, 415-419.	0.9	18
115	Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 69, S4-S10.	0.9	17
116	Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 269.	0.7	17
117	Second-line treatments of small-cell lung cancers. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1033-1043.	1.1	17
118	Analysis of health economics assessment reports for pharmaceuticals in France " understanding the underlying philosophy of CEESP assessment. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1344088.	0.8	17
119	Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review. <i>ClinicoEconomics and Outcomes Research</i> , 2014, 7, 9.	0.7	16
120	Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study. <i>Targeted Oncology</i> , 2016, 11, 167-174.	1.7	16
121	Association between lung cancer somatic mutations and occupational exposure in never-smokers. <i>European Respiratory Journal</i> , 2017, 50, 1700716.	3.1	16
122	Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE). <i>Oncology</i> , 2018, 94, 55-64.	0.9	16
123	Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France. <i>Oncology</i> , 2018, 95, 337-343.	0.9	16
124	Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC). <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 519-528.	0.7	16
125	Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). <i>Lung Cancer</i> , 2019, 136, 109-114.	0.9	16
126	I-O Optimise: a novel multinational real-world research platform in thoracic malignancies. <i>Future Oncology</i> , 2019, 15, 1551-1563.	1.1	16

#	ARTICLE	IF	CITATIONS
127	Nivolumab-refractory patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 130, 128-134.	0.9	16
128	Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy. <i>Current Medical Research and Opinion</i> , 2009, 25, 1455-1460.	0.9	15
129	Perception of alopecia by patients requiring chemotherapy for non-small-cell lung cancer: A willingness to pay study. <i>Lung Cancer</i> , 2011, 72, 114-118.	0.9	15
130	EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients. <i>Lung Cancer</i> , 2016, 96, 74-77.	0.9	15
131	Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis. <i>Cancer Medicine</i> , 2018, 7, 1102-1109.	1.3	15
132	New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4051-4064.	1.0	15
133	Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis. <i>Targeted Oncology</i> , 2022, 17, 153-166.	1.7	15
134	Standardized Protocol Improves Asthma Management in Emergency Department. <i>Journal of Asthma</i> , 2004, 41, 19-25.	0.9	14
135	Assessment of palliative care for advanced non-small-cell lung cancer in France: A prospective observational multicenter study (GFPC 0804 study). <i>Lung Cancer</i> , 2013, 82, 353-357.	0.9	14
136	What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients? Results from the lung cancer economics and outcomes research (LUCEOR) study. <i>Lung Cancer</i> , 2013, 82, 128-135.	0.9	14
137	Lung cancer survivors and employment: A systematic review. <i>Lung Cancer</i> , 2019, 131, 31-39.	0.9	14
138	First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097713.	1.4	14
139	Interstitial Lung Disease Associated with Lung Cancer: A Case-Control Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 700.	1.0	14
140	Empyema of the thorax due to <i>Gemella haemolysans</i> . <i>Journal of Infection</i> , 1999, 39, 245-246.	1.7	13
141	Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2010, 69, S24-S30.	0.9	13
142	Cutaneous lymphangitis carcinomatosa in a patient with lung adenocarcinoma: Case report and literature review. <i>Lung Cancer</i> , 2013, 79, 91-93.	0.9	13
143	Current process and future path for health economic assessment of pharmaceuticals in France. <i>Journal of Market Access & Health Policy</i> , 2015, 3, 27902.	0.8	13
144	Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802) <small>Tj ETQq0 Q0 rgBT /Qverlock 10</small>	1.1	13

#	ARTICLE	IF	CITATIONS
145	Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France. <i>Current Medical Research and Opinion</i> , 2019, 35, 785-792.	0.9	13
146	Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine+atezolizumab combination for stage-IV non-small-cell lung cancer – VinMetAtezo trial, (GFPC 04-2017). <i>Future Oncology</i> , 2020, 16, 5-10.	1.1	13
147	Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096723.	1.4	13
148	Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients. <i>Cancers</i> , 2021, 13, 1040.	1.7	13
149	Simulation-Based Estimates of the Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease in France. <i>PLoS ONE</i> , 2016, 11, e0156514.	1.1	13
150	A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes. <i>Targeted Oncology</i> , 2021, 16, 801-811.	1.7	13
151	Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review. <i>Lung Cancer</i> , 2022, 166, 205-220.	0.9	13
152	A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1203-1208.	1.1	12
153	Cost effectiveness of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504). <i>BMC Cancer</i> , 2012, 12, 301.	1.1	12
154	Cost Analysis of Erlotinib Versus Chemotherapy for First-Line Treatment of Non-Small-Cell Lung Cancer in Frail Elderly Patients Participating in a Prospective Phase 2 Study (GFPC 0505). <i>Clinical Lung Cancer</i> , 2013, 14, 103-107.	1.1	12
155	Efficacy of Pemetrexed as Second-Line Therapy in Advanced NSCLC after Either Treatment-Free Interval or Maintenance Therapy with Gemcitabine or Erlotinib in IFCT-GFPC 05-02 Phase III Study. <i>Journal of Thoracic Oncology</i> , 2013, 8, 906-914.	0.5	12
156	Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin+gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study. <i>BMC Cancer</i> , 2014, 14, 953.	1.1	12
157	A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2015, 20, 783-790.	0.5	12
158	Second-Line Oral Chemotherapy (Lomustine, Cyclophosphamide, Etoposide) Versus Intravenous Therapy (Cyclophosphamide, Doxorubicin, and Vincristine) in Patients With Relapsed Small Cell Lung Cancer: A Randomized Phase II Study of GFPC 0501. <i>Clinical Lung Cancer</i> , 2015, 16, 100-105.	1.1	12
159	A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer. <i>Lung Cancer</i> , 2015, 90, 397-404.	0.9	12
160	Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group. <i>Journal of Thoracic Disease</i> , 2017, 9, 3747-3754.	0.6	12
161	Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 655-668.	0.7	11
162	Beclin1 circulating levels and accelerated aging markers in COPD. <i>Cell Death and Disease</i> , 2018, 9, 156.	2.7	11

#	ARTICLE	IF	CITATIONS
163	Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 981-989.	1.1	11
164	Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02â€™14. <i>Advances in Therapy</i> , 2019, 36, 2161-2166.	1.3	11
165	Clinical efficacy and cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration for preoperative staging of non-smallâ€™cell lung cancer: Results of a French prospective multicenter trial (EVIEPEB). <i>PLoS ONE</i> , 2019, 14, e0208992.	1.1	11
166	<p>Targeting the MET-Signaling Pathway in Non-Smallâ€™Cell Lung Cancer: Evidence to Date</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5691-5706.	1.0	11
167	Diagnosis of nosocomial pneumonia in medical ward: repeatability of the protected specimen brush. <i>European Respiratory Journal</i> , 2001, 18, 157-163.	3.1	10
168	Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study). <i>Lung Cancer</i> , 2015, 89, 139-145.	0.9	10
169	Factors associated with excessively lengthy treatment of tuberculosis in the eastern Paris region of France in 2004. <i>BMC Public Health</i> , 2010, 10, 495.	1.2	9
170	Impaired humoral and cellular immune responses to influenza vaccination in chronic obstructive pulmonary disease patients. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1754-1757.e6.	1.5	9
171	Cost analysis of adverse events associated with non-small cell lung cancer management in France. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 443-449.	0.7	9
172	A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 505-518.	0.7	9
173	Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-smallâ€™cell lung cancers: An open phase II study using concurrent cisplatinâ€™oral vinorelbine and radiotherapy (GFPC 08-06). <i>Lung Cancer</i> , 2018, 121, 25-29.	0.9	9
174	A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an Early Modification of Chemotherapy Doublet with Paclitaxel-Gemcitabine Versus Continuation of Cisplatin-Gemcitabine Chemotherapy (GFPC 03-01) Tj ETQq0 00TgBT /Overlock 10	0.5	8
175	Optimization of Small-Cell Lung Cancer Chemotherapy with Heparin: A Comprehensive Retrospective Study of 239 Patients Treated in a Single Specialized Center. <i>Chemotherapy</i> , 2011, 57, 253-258.	0.8	8
176	French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends. <i>Targeted Oncology</i> , 2016, 11, 515-534.	1.7	8
177	Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank. <i>BMC Public Health</i> , 2017, 17, 324.	1.2	8
178	Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02â€™14 Study). <i>Targeted Oncology</i> , 2017, 12, 833-838.	1.7	8
179	Real-life experience of ceritinib in crizotinib-pretreated <i>ALK</i>⁺ advanced non-small cell lung cancer patients. <i>ERJ Open Research</i> , 2018, 4, 00058-2017.	1.1	8
180	Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1159-1165.	1.1	8

#	ARTICLE	IF	CITATIONS
181	Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019. <i>Cancers</i> , 2020, 12, 3608.	1.7	8
182	Factors associated with early lung cancer mortality: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1125-1133.	1.1	8
183	Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study. <i>Cancers</i> , 2022, 14, 1498.	1.7	8
184	Targeted Therapies in Non-Small-Cell Lung Cancer Management: No Cost-Effective Strategies?. <i>Journal of Clinical Oncology</i> , 2014, 32, 3577-3577.	0.8	7
185	Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer. <i>Targeted Oncology</i> , 2019, 14, 307-314.	1.7	7
186	Impact on All-Cause and Cardiovascular Mortality Rates of Coronary Artery Calcifications Detected during Organized, Low-Dose, Computed-Tomography Screening for Lung Cancer: Systematic Literature Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1553.	1.7	7
187	Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20522-e20522.	0.8	7
188	First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score $\geq 50\%$) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study). <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 91-99.	2.0	7
189	The Cost of Lung Cancer Management in France from the Payor's Perspective. <i>Disease Management and Health Outcomes</i> , 2006, 14, 55-67.	0.3	6
190	Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study. <i>BMC Cancer</i> , 2018, 18, 1013.	1.1	6
191	Are Systemic Manifestations Ascribable to COPD in Smokers? A Structural Equation Modeling Approach. <i>Scientific Reports</i> , 2018, 8, 8569.	1.6	6
192	First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression $\geq 50\%$. <i>Future Oncology</i> , 2021, 17, 3007-3016.	1.1	6
193	First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data. <i>BioDrugs</i> , 2022, 36, 137-151.	2.2	6
194	Treatment of lung cancer: will financial issues become a criterion of choice?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 273-275.	0.7	5
195	Current Process and Future Path for Health Economic Assessment of Pharmaceuticals in France. <i>Value in Health</i> , 2015, 18, A521.	0.1	5
196	PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 609-619.	0.2	5
197	Isolated 5q ⁻ Signals Are an Atypical Pattern To Be Considered as Positive for ALK Rearrangement: A Brief Report of Three Cases and Review of the Literature. <i>Translational Oncology</i> , 2019, 12, 784-787.	1.7	5
198	Duration of nivolumab for pretreated, advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2020, 9, 6923-6932.	1.3	5

#	ARTICLE	IF	CITATIONS
199	Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined. <i>Translational Lung Cancer Research</i> , 2020, 9, 1732-1735.	1.3	5
200	<p>Impact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2905-2915.	0.9	4
201	Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14). <i>Current Oncology</i> , 2021, 28, 3804-3811.	0.9	4
202	Study ESOGIA-GFPC 08-02: Phase III, randomized, multicenter trial involving subjects over age 70 with stage IV non-small cell lung cancer and comparing a "classical" strategy of treatment allocation (dual-agent therapy based on carboplatin or monotherapy with docetaxel alone), based on performance status and age, with an "optimized" strategy allocating the same treatments according to a simplified geriatric screening scale, plus a more thorough geriatric evaluation if necessary.. <i>Journal of Clinical Oncology</i> , 2011, 29, TPS219-TPS219.	0.8	4
203	Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study. <i>Future Oncology</i> , 2020, 16, 1115-1124.	1.1	4
204	Machine Learning-Based Analysis of Treatment Sequences Typology in Advanced Non-Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100108.	1.0	4
205	Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study. <i>Cancers</i> , 2022, 14, 1751.	1.7	4
206	Analysis of COVID-19 inpatients in France during first lockdown of 2020 using explainability methods. <i>Medical and Biological Engineering and Computing</i> , 2022, 60, 1647-1658.	1.6	4
207	Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: A GFPC study. <i>Lung Cancer</i> , 2011, 74, 264-267.	0.9	3
208	An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer. <i>Current Medical Research and Opinion</i> , 2011, 27, 2193-2201.	0.9	3
209	Febrile neutropenia prophylaxis, G-CSF physician preferences: discrete-choice experiment. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2021-003082.	0.8	3
210	Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience. <i>Cancers</i> , 2022, 14, 92.	1.7	3
211	Risk factors for early mortality of lung cancer patients in France: A nationwide analysis. <i>Cancer Medicine</i> , 2022, 11, 5025-5034.	1.3	3
212	Efficacy and toxicity of mitomycin, ifosfamide, and cisplatin (MIP) in patients with inoperable non-small cell lung cancer. <i>Lung Cancer</i> , 1996, 14, 109-117.	0.9	2
213	O-091 A randomized phase II trial of docetaxel alone and in combination with gefitinib (IRESSA) as second-line therapy for patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2005, 49, S33.	0.9	2
214	PCN3 ECONOMIC IMPACT OF SECOND- AND THIRD-LINE ERLOTINIB TREATMENT OF NON SMALL-CELL LUNG CANCER: A FRENCH OBSERVATIONAL STUDY. <i>Value in Health</i> , 2007, 10, A322.	0.1	2
215	PCN84 COST-EFFECTIVENESS OF ERLOTINIB IN FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FIT ELDERLY PATIENTS: AN ECONOMICAL ANALYSIS OF A PROSPECTIVE PHASE 2 STUDY (GFPC 0504). <i>Value in Health</i> , 2010, 13, A267.	0.1	2
216	PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: A Markov Model. <i>Value in Health</i> , 2011, 14, A454.	0.1	2

#	ARTICLE	IF	CITATIONS
217	PCN37 Cost-Minimization Analysis of Second-Line Chemotherapy for Non-Small-Cell Lung Cancer (NSCLC). Value in Health, 2011, 14, A440.	0.1	2
218	Multidimensional analyses to assess the relations between treatment choices by physicians and patients' characteristics: the example of COPD. BMC Pulmonary Medicine, 2012, 12, 39.	0.8	2
219	Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy. Expert Review of Anticancer Therapy, 2015, 15, 121-128.	1.1	2
220	Burden of Disease And Management of Mesothelioma In France: A National Cohort Analysis. Value in Health, 2016, 19, A621.	0.1	2
221	Reply to R.D. Nipp et al, M.-J. Molina-Garrido et al, and A. Gajra et al. Journal of Clinical Oncology, 2016, 34, 4050-4051.	0.8	2
222	Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus repeat progression cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110069.	1.4	2
223	Patient (Pt) and caregiver (Cg) perspectives in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, 4-4.	0.8	2
224	Anti PD-1 (nivolumab, pembrolizumab) or anti PD-L1 (atezolizumab) versus docetaxel for previously treated patients with advanced NSCLC: A meta-analysis.. Journal of Clinical Oncology, 2016, 34, e20555-e20555.	0.8	2
225	Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France. Journal of Medical Economics, 2022, 25, 691-699.	1.0	2
226	Attitudes to prevention among HIV-infected patients: the case of specific prophylaxis for Pneumocystis carinii pneumonia. Health Policy, 1994, 27, 253-259.	1.4	1
227	O-060 Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anemia: A Markov analysis. Lung Cancer, 2005, 49, S23.	0.9	1
228	PCN10 INCREMENTAL COST-EFFECTIVENESS RATIO OF DARBEPOETIN ALFA (ARANESPÂ®) IN THE TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA IN LUNG CANCER PATIENTS. Value in Health, 2006, 9, A278-A279.	0.1	1
229	Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study. Targeted Oncology, 2007, 2, 63-71.	1.7	1
230	PCN43 THE COST OF TREATING GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINOURELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE. Value in Health, 2009, 12, A264.	0.1	1
231	PCN125 AN ECONOMICAL, RANDOMIZED, MULTICENTER PHASE III TRIAL OF SECOND LINE TREATMENT FOR NON SMALL CELL LUNG CANCER (NSCLC) COMPARING DOCETAXEL VERSUS PEMETREXED: GFPC (GROUPE) Tj ET Qq1 1 0.784314 rg8T	0.1	1
232	PCN21 FIRST-LINE BEVACIZUMAB-BASED THERAPY VERSUS PEMETREXED + CISPLATIN FOR THE TREATMENT OF ADVANCED ADENOCARCINOMA NONSQUAMOUS NON-SMALL CELL LUNG CANCER: INDIRECT COMPARISON APPLYING REAL-LIFE OUTCOMES. Value in Health, 2010, 13, A255.	0.1	1
233	PCN81 COST-EFFECTIVENESS ANALYSIS OF THREE STRATEGIES OF ERLOTINIB TREATMENT IN NONO-SMALL-CELL LUNG CANCER:A PROSPECTIVE MULTICENTRIC FRENCH STUDY (ERMETIC). Value in Health, 2010, 13, A266.	0.1	1
234	PRS9 QUALITY OF LIFE AND ECONOMIC IMPACT OF ASTHMA CONTROL IN FRANCE AND SPAIN. FIRST RESULTS OF THE EU-COAST STUDY. Value in Health, 2010, 13, A320.	0.1	1

#	ARTICLE	IF	CITATIONS
235	PCN8 REAL LIFE OUTCOMES IN 1ST LINE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A PILOT STUDY IN FRANCE AND GERMANY ANALYSING BEVACIZUMAB-BASED VERSUS NON-BEVACIZUMAB-BASED TREATMENTS. Value in Health, 2011, 14, A156.	0.1	1
236	PCN94 HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN 1ST LINE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS IN A REAL LIFE SETTING: BEVACIZUMAB-BASED VERSUS NON-BEVACIZUMAB BASED THERAPY IN A EUROPEAN PILOT STUDY. Value in Health, 2011, 14, A171.	0.1	1
237	PCN79 Cost Effectiveness of Erlotinib in First Line Treatment of Advanced Non Small Cell Lung Cancer (NSCLC) in Vulnerable Elderly Patients: An Economical Analysis of a prospective Phase 2 Study (GFPC) Tj ETQq1 1 0.784314 r gBT /Overlock 10 Tf 5	0.1	1
238	TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results. International Journal of Radiation Oncology Biology Physics, 2014, 90, S35.	0.4	1
239	French Health Technology Assessment Of Antineoplastic Drugs Indicated In The Treatment Of Solid Tumours: Perspective For Future Trends. Value in Health, 2015, 18, A489.	0.1	1
240	Access to Innovative Drugs in Patients with Metastatic Lung Cancer in French Public Hospitals (the) Tj ETQq0 0 0 r gBT /Overlock 10 Tf 5	0.1	1
241	Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (Esmo-Mcsb) and the American Society of Clinical Oncology (Asco) Framework for Assessing Value in Cancer Care. Value in Health, 2016, 19, A357.	0.1	1
242	Costs of Adverse Events Associated with Cancer Therapies in Non-Small Cell Lung Cancer in France. Value in Health, 2016, 19, A743.	0.1	1
243	Non small cell lung cancer (NSCLC) patients harboring BRAF mutation: Clinical characteristics and management in real world setting. Cohort BRAF EXPLORE GFPC 02-14. Annals of Oncology, 2016, 27, vi439.	0.6	1
244	P2.06-024 Tedopi vs Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Advanced NSCLC Patients in a Phase 3, Randomized Trial: ATALANTE-1. Journal of Thoracic Oncology, 2017, 12, S1085-S1086.	0.5	1
245	Author's Reply to Arnaud Uguen: "Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC) Tj ETQq1 1 0.784314 r gBT /Overlock 10 Tf 5	0.1	1
246	Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer " Authors' reply. Lancet Oncology, The, 2020, 21, e546.	5.1	1
247	Monitoring Subsolid Pulmonary Nodules in High-Risk Patients Is Even More Cost-Effective When Combined With a Stop-Smoking Program. Journal of Thoracic Oncology, 2020, 15, 1268-1270.	0.5	1
248	Economic analyses of immune-checkpoint inhibitors to treat lung cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 365-371.	0.7	1
249	A multicenter phase II randomized study of docetaxel (D)/gemcitabine (G) weekly followed by erlotinib (E) after progression versus erlotinib followed by docetaxel/gemcitabine after progression in advanced non-small cell lung cancer (NSCLC) in fit elderly patients selected with a comprehensive geriatric assessment (CGA): Groupe Français de Pneumocancerologie (GFPC)*0504.. Journal of Clinical Oncology, 2018, 28, 7536-7536.	0.8	1
250	Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in france after a first-line platinum based therapy. , 2017, , .		1
251	Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small-Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study). OncoTargets and Therapy, 2020, Volume 13, 13299-13305.	1.0	1
252	PD6-3-3: Medical and economical impact of bone metastases in lung cancer patients: a prospective French national, multicentric study (GFPC 06-01 study). Journal of Thoracic Oncology, 2007, 2, S432.	0.5	0

#	ARTICLE	IF	CITATIONS
253	PCN92 VALUE OF ALOPECIA FOR LUNG CANCER PATIENT TREATED BY SECOND LINE CHEMOTHERAPY: A WILLINGNESS TO PAY STUDY. Value in Health, 2008, 11, A489.	0.1	0
254	PCN14 AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC). Value in Health, 2009, 12, A258.	0.1	0
255	PCN67 LOWER ADMINISTRATION COSTS OF BEVACIZUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY VERSUS CETUXIMAB-VINORELBINE-CISPLATIN THERAPY FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) FOCUSING ON THREE EUROPEAN HEALTH CARE SYSTEMS. Value in Health, 2009, 12, A269.	0.1	0
256	PCN97 COST EFFECTIVENESS OF ERLOTINIB TREATMENT GIVEN BY A CLINICALLY BASED APPROACH AND AN EGFR/KRAS TESTING-GUIDED APPROACH ADVANCED IN NON SMALL-CELL LUNG CANCER: A PROSPECTIVE MULTICENTRIC FRENCH STUDY (ERMETIC). Value in Health, 2009, 12, A275.	0.1	0
257	PCN161 REIMBURSEMENT OF ADMINISTRATION COSTS ARE UNAFFECTED BY SINGLE, DOUBLE OR TRIPLE ANTI-CANCER THERAPY COMBINATIONS IN THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) IN FRANCE AND GERMANY. Value in Health, 2009, 12, A288.	0.1	0
258	PCN9 OBSERVATIONAL STUDY OF PATIENTS WITH NON SMALL CELL LUNG CANCER (NSCLC) TREATED BY ERLOTINIB: CLINICAL PRACTICES AND MAIN OUTCOMES IN FRANCE. Value in Health, 2010, 13, A252.	0.1	0
259	PCN16 MIXED TREATMENT COMPARISON OF BEVACIZUMAB-BASED THERAPIES RELATIVE TO DOUBLET-CHEMOTHERAPY COMBINATIONS TO ESTIMATE THE RELATIVE EFFICACY IN PROGRESSION-FREE SURVIVAL FOR TREATMENT OF FIRST-LINE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC). Value in Health, 2010, 13, A253-A254.	0.1	0
260	PRS19 Quality of Life and Economics of Asthma Control in France and Spain: Final Results of the EU-Coast Study. Value in Health, 2011, 14, A490.	0.1	0
261	9076 POSTER An Interim Analysis of Health-Related Quality of Life (HRQoL) in Patients With Non-Squamous Non-Small-Cell Lung Cancer (nsNSCLC) Receiving Bevacizumab Vs Bevacizumab+Pemetrexed for Maintenance Therapy in AVAPERL 1. European Journal of Cancer, 2011, 47, S615.	1.3	0
262	PCN13 REAL LIFE OUTCOMES IN 2ND LINE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A PILOT STUDY IN FRANCE AND GERMANY ANALYSING ERLOTINIB VERSUS CHEMOTHERAPY. Value in Health, 2011, 14, A157.	0.1	0
263	PCN126 OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE. Value in Health, 2011, 14, A177-A178.	0.1	0
264	PCN42 Treatment Costs of Bone Metastases in Patients with Lung Cancer: Results From A French Prospective, Observational, Multicenter Study (GFPC 0601). Value in Health, 2011, 14, A441.	0.1	0
265	PRS46 Effectiveness and Cost-Utility Estimates of Tiotropium Treatment and Pulmonary Rehabilitation Programs in French Patients with Chronic Obstructive Pulmonary Disease. Value in Health, 2011, 14, A495-A496.	0.1	0
266	PCN110 Health-Related Quality of Life in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. Value in Health, 2012, 15, A227.	0.1	0
267	PCN9 From Indirect Evidence to Direct Evidence: A Real-World Example for the Value of Indirect Treatment Comparisons in Second-Line NSCLC Therapy. Value in Health, 2012, 15, A209.	0.1	0
268	Costs of COPD in France: A National Database Analysis. Value in Health, 2013, 16, A370.	0.1	0
269	Reply to N. Singh et al. Journal of Clinical Oncology, 2013, 31, 1251-1252.	0.8	0
270	Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents. ClinicoEconomics and Outcomes Research, 2013, 5, 137.	0.7	0

#	ARTICLE	IF	CITATIONS
271	Lung Cancer in Patients Under 40 Years: a Prospective Observational Multicenter Study (Groupe) Tj ETQq1 1 0.784314 rgBT /Overloc	0.6	0
272	Companion Diagnostics-Targeted Therapies Pairings Model-Based Economic Evaluation: Reflection On A General Modeling Framework And Key Methodological Points. Value in Health, 2014, 17, A565.	0.1	0
273	Simulation and Comparison of Progression-Free Survival (Pfs) Among Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Therapy. Value in Health, 2014, 17, A70.	0.1	0
274	3105 Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial. European Journal of Cancer, 2015, 51, S637.	1.3	0
275	Is Oncology Drug Financial Toxicity A Specific Us Issue?. Value in Health, 2015, 18, A573.	0.1	0
276	3062 Ceritinib following crizotinib in ALK-positive (+) advanced NSCLC patients (pts): Results from the French Temporary Authorization for Use (ATU) experience. European Journal of Cancer, 2015, 51, S616-S617.	1.3	0
277	Expected Impact of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (Esmo-Mcsb) on Health Technology Assessment. Value in Health, 2016, 19, A358-A359.	0.1	0
278	The American Society of Clinical Oncology (Asco) Net Health Benefit (Nhb) Assessment Tool: Which Implications for Value Assessment of Cancer Therapies?. Value in Health, 2016, 19, A359-A360.	0.1	0
279	Development of a Questionnaire for the Search for Occupational Causes in Patients with Non-Hodgkin Lymphoma: The RHELYPRO Study. International Journal of Environmental Research and Public Health, 2021, 18, 4008.	1.2	0
280	PD4-3-7: Multicentric phase II trial of Cisplatin plus Etoposide chemotherapy in advanced Large-Cell Neuro Endocrine Carcinoma of the Lung (LCNEC): preliminary results. Study 03-02 from the "Groupe Francais de Pneumo-Cancerologie (GFPC). Journal of Thoracic Oncology, 2007, 2, S457.	0.5	0
281	"Regards Crois" 2009: French survey about perception and management of fatigue-related cancer.. Journal of Clinical Oncology, 2010, 28, e19653-e19653.	0.8	0
282	Observational study of patients with non-small cell lung cancer (NSCLC) treated by erlotinib: Clinical practices and main outcomes in France (OBSTAR).. Journal of Clinical Oncology, 2010, 28, e12031-e12031.	0.8	0
283	A multicenter phase II randomized study of gemcitabine (G) weekly followed by erlotinib (E) after progression versus E followed by G after progression in advanced non-small cell lung cancer (NSCLC) in vulnerable elderly patients selected with a comprehensive geriatric assessment (CGA) (GFPC*0505).. Journal of Clinical Oncology, 2010, 28, e18002-e18002.	0.8	0
284	Multicentric phase II trial of cisplatin/etoposide chemotherapy in advanced large-cell neuroendocrine carcinoma of the lung (LCNEC): Study GFPC 03-02 from the Groupe Francais de Pneumo-cancerologie.. Journal of Clinical Oncology, 2010, 28, e18018-e18018.	0.8	0
285	ESOGIA: a "first step" for comprehensive geriatric assessment-guided treatment in non-small cell lung cancer. Translational Cancer Research, 2016, 5, S371-S373.	0.4	0
286	Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-mutated population with advanced non-small-cell lung cancer.. Journal of Clinical Oncology, 2017, 35, e20548-e20548.	0.8	0
287	Management of patients with head and neck cancer (HNC) and synchronic stage I or II lung cancer. SYNCHRON GFPC 15-01 study.. Journal of Clinical Oncology, 2017, 35, e20048-e20048.	0.8	0
288	Beclin1 circulating levels and accelerated ageing markers in COPD. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
289	Efficacy of next treatment received after Nivolumab (Nivo) progression in patients (pts) with non-small-cell lung cancer (NSCLC). , 2017, , .		0
290	Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-Mutated population with advanced non-small-cell lung cancer. , 2017, , .		0